In the latest trading session, Amgen (AMGN) closed at $272.11, marking a +0.99% move from the previous day.
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.
In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen Inc. (NASDAQ:AMGN ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 6:00 PM ET Company Participants Robert Bradway - Chairman, CEO & President Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen (AMGN) closed at $262.05 in the latest trading session, marking a +1.34% move from the prior day.
Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Since my previous article, shares of Amgen meaningfully lagged the S&P 500 index. The company's revenue and non-GAAP EPS climbed higher in the third quarter. Amgen's deleveraging efforts are progressing, and the company is on pace to return to its pre-Horizon capital structure by the end of 2025.